Ansh Enterprises

Lapatinib is used to treat a certain type of breast cancer (HER2-positive). It works by slowing or stopping the growth of cancer cells.
How to use Lapatinib 250 Mg Tablet Antineoplastic - Protein-Tyrosine Kinase Inhibitors
Read the Patient Information Leaflet provided by your pharmacist before you start using lapatinib and each time you get a refill. If you have any questions, consult your doctor or pharmacist.
Take this medication by mouth 1 hour before or 1 hour after a meal, usually once daily or as directed by your doctor. It is important that you do not take this medication more than once daily.
The dosage is based on your medical condition, response to treatment, and certain other drugs you may be taking.
Do not increase your dose or take this medication more often than prescribed. Your condition will not improve any faster, and the risk of serious side effects may be increased.

Imatinib 400 mg

Tucatinib is a type of targeted anticancer drug, which is used in combination with other medications for the treatment of advanced breast cancer. Tucatinib belongs to a class of drugs called tyrosine kinase inhibitors.

Tucatinib targets HER2 (human epidermal growth factor receptor 2) tyrosine kinase. HER2 receptors are involved in the growth and repair of normal breast cells. But, 10 to 20 percent of breast cancers have a faulty HER2 gene, which makes too many copies of itself. This results in HER2 protein overexpression - too many HER2 receptors on the breast cells - which makes the breast cells grow and divided uncontrollably.

Tucatinib works by blocking the activity of HER2, which helps to slow the growth and spread of cancer cells. It is used in combination with trastuzumab and capecitabine because the combination helps patients live longer without their cancer progressing and survive for longer overall.

It was approved by the US Food and Drug Administration (FDA) in 2020.

Tucatinib is a type of targeted anticancer drug, which is used in combination with other medications for the treatment of advanced breast cancer. Tucatinib belongs to a class of drugs called tyrosine kinase inhibitors.

Tucatinib targets HER2 (human epidermal growth factor receptor 2) tyrosine kinase. HER2 receptors are involved in the growth and repair of normal breast cells. But, 10 to 20 percent of breast cancers have a faulty HER2 gene, which makes too many copies of itself. This results in HER2 protein overexpression - too many HER2 receptors on the breast cells - which makes the breast cells grow and divided uncontrollably.

Tucatinib works by blocking the activity of HER2, which helps to slow the growth and spread of cancer cells. It is used in combination with trastuzumab and capecitabine because the combination helps patients live longer without their cancer progressing and survive for longer overall.

It was approved by the US Food and Drug Administration (FDA) in 2020.